title: Interleukin-18 (IL-18) and matrix metalloproteinase-9 (MMP-9) in post-menopausal osteoporosis.
abstract: This survey covered 60 post-menopausal women with osteoporosis. The patients were divided into three equal groups, and each group was treated with one of the three so-called anti-resorptive drugs, namely alendronate (10 mg/day) risedronate (5 mg/day) and raloxifene (60 mg/day) for 12 months. The Elisa technique was used to measure circulating IL-18 and MMP-9. Lumbar bone mineral density (BMD) levels were determined by using dexa mineralometry (Lunar DPX) at baseline and after 12 months of treatment. The results showed comparable responses of the patients treated with alendronate or risedronate, being a significant increase in BMD, an increase in circulating IL-18, and only slight modifications in circulating MMP-9 levels. After 12 months of treatment with raloxifene, there were minimal, non-significant increases in BMD, slight modifications in IL-18 levels, and a significant reduction in circulating MMP-9 levels. The conclusions can be drawn that all three drugs, albeit through different mechanisms, can be considered valid treatments for post-menopausal osteoporosis. Although measurements of circulating IL-8 and MMP-9 levels allowed us to differentiate the effects of the three drugs used, as of today, they have no real role in the diagnosis and/or follow-up of osteoporosis.
authors.affiliation: Department of Senescent, Urological and Neurourological Sciences, University of Catania, Cannizzaro Hospital, Via Messina, 829, I-95126 Catania, Italy. dmaugeri@tin.it
authors.forename: D
authors.initials: D
authors.lastname: Maugeri
authors.forename: C
authors.initials: C
authors.lastname: Mamazza
authors.forename: F
authors.initials: F
authors.lastname: Lo Giudice
authors.forename: N
authors.initials: N
authors.lastname: Puglisi
authors.forename: E G
authors.initials: EG
authors.lastname: Muscoso
authors.forename: M
authors.initials: M
authors.lastname: Rizzotto
authors.forename: M
authors.initials: M
authors.lastname: Testaì
authors.forename: E
authors.initials: E
authors.lastname: Bennati
authors.forename: A
authors.initials: A
authors.lastname: Lentini
authors.forename: P
authors.initials: P
authors.lastname: Panebianco
mesh_terms: D019386:Alendronate / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects*; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D020382:Interleukin-18 / Q000097:blood*; D020780:Matrix Metalloproteinase 9 / Q000097:blood*; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D000068296:Risedronic Acid; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*
chemical_list: D020382:Interleukin-18; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D020780:Matrix Metalloproteinase 9; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate